Astellas Pharma Global Development, Inc.

ARCHES | 9785-CL-0335

NCT02677896

JCP011

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

Roll over

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Enzalutamide

Nonsteroidal Antiandrogen (p.o.)

Treatment Arms

o Experimental: Enzalutamide + Androgen Deprivation Therapy (ADT)

o Placebo Comparator: Placebo + Androgen Deprivation Therapy (ADT